Mifegymiso Added to Saskatchewan Drug Formulary

Released on August 31, 2017

Effective September 5, the Saskatchewan Prescription Drug Plan will provide coverage for the drug Mifegymiso (mifepristone and misoprostol).

Mifegymiso is the first oral medication approved by Health Canada for medical termination of a pregnancy (abortion) up to 49 days.  Mifegymiso has been reviewed through the usual Formulary listing process, including review by the national Common Drug Review and the Drug Advisory Committee of Saskatchewan.  Both were supportive of listing Mifegymiso on the Saskatchewan Formulary.

Listing this product follows the outcome of the review process, and provides coverage in the same manner as other medications listed on the Saskatchewan Formulary.

Saskatchewan joins several other provinces including Alberta, British Columbia, Manitoba, New Brunswick, Ontario and Quebec in offering access to Mifegymiso.

As per Health Canada guidelines, prescribers must complete required training before they can prescribe Mifegymiso to their patients.  Patients should contact their physician or authorized prescriber for more information on how to access treatment with Mifegymiso.

The cost charged to a patient will vary based on their individual drug coverage and eligibility through benefit programs.

The Saskatchewan Formulary currently lists more than 5,400 drug products as benefits under the Drug Plan.

Since 2007, the Government of Saskatchewan has increased funding to the Drug Plan by approximately $54 million or 18 per cent.

-30-

For more information, contact:

Shirley Xie
Health
Regina
Phone: 306-787-4083
Email: Shirley.Xie@health.gov.sk.ca